JP2008013442A - Rough skin improving agent - Google Patents
Rough skin improving agent Download PDFInfo
- Publication number
- JP2008013442A JP2008013442A JP2006183235A JP2006183235A JP2008013442A JP 2008013442 A JP2008013442 A JP 2008013442A JP 2006183235 A JP2006183235 A JP 2006183235A JP 2006183235 A JP2006183235 A JP 2006183235A JP 2008013442 A JP2008013442 A JP 2008013442A
- Authority
- JP
- Japan
- Prior art keywords
- improving agent
- rough skin
- ovarian
- intake
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002611 ovarian Effects 0.000 claims abstract description 34
- 241000251468 Actinopterygii Species 0.000 claims abstract description 10
- 102000035195 Peptidases Human genes 0.000 claims abstract description 6
- 108091005804 Peptidases Proteins 0.000 claims abstract description 6
- 239000012528 membrane Substances 0.000 claims description 29
- 241000382353 Pupa Species 0.000 claims description 2
- 235000019688 fish Nutrition 0.000 abstract description 9
- 241000972773 Aulopiformes Species 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 235000013402 health food Nutrition 0.000 abstract description 3
- 235000019515 salmon Nutrition 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 description 27
- 230000037303 wrinkles Effects 0.000 description 19
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 18
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 18
- 239000000902 placebo Substances 0.000 description 15
- 229940068196 placebo Drugs 0.000 description 15
- 230000037406 food intake Effects 0.000 description 12
- 206010013786 Dry skin Diseases 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本発明は、肌荒れ改良剤に関するものである。 The present invention relates to a rough skin improving agent.
従来、魚類の卵巣膜（魚卵外皮）を予めオゾン水で処理した後、その構成タンパク質である筋原線維タンパク質を酵素分解してアミノ酸及びペプチドを抽出する方法が知られている（例えば特許文献１参照）。 Conventionally, a method of extracting amino acids and peptides by treating the ovarian membrane (fish egg rind) of fish with ozone water in advance and then enzymatically degrading myofibrillar protein, which is a constituent protein thereof, is known (for example, patent document). 1).
前記アミノ酸及びペプチドは、生理活性物質として、あるいは食品強化剤として用いることができるとされており、さらに詳しくは、ＡＣＥ阻害活性を備え、血圧上昇抑制剤（降圧剤）として作用するとされている。 The amino acids and peptides can be used as physiologically active substances or as food fortifiers. More specifically, the amino acids and peptides have ACE inhibitory activity and act as blood pressure increase inhibitors (hypertensive agents).
しかしながら、魚類の卵巣膜から抽出された成分には、さらに多くの用途の開発が望まれる。
本発明は、かかる事情に鑑み、魚類の卵巣膜から抽出された成分の新たな用途を提供することを目的とする。 In view of such circumstances, an object of the present invention is to provide a new use of a component extracted from the ovarian membrane of fish.
かかる目的を達成するために、本発明の肌荒れ改良剤は、魚類の卵巣膜から抽出された成分を含むことを特徴とする。 In order to achieve this object, the rough skin improving agent of the present invention is characterized by containing a component extracted from the ovarian membrane of fish.
生体においては、成年期を過ぎると加齢に伴って、肌の肌理が粗くなる、つややはりが無くなる、シワが深くなる等の肌荒れの諸症状が現れてくる。また、若年層においても、水分不足やストレス等によって肌のかさつき、吹き出物ができる等の肌荒れの諸症状を訴える人が多い。 In the living body, after the adulthood, with the aging, various symptoms of rough skin such as rough skin, loss of gloss, and deep wrinkles appear. In addition, many young people complain of various symptoms of rough skin, such as skin irritation and pimples due to lack of moisture or stress.
ところが、本発明の肌荒れ改良剤によれば、肌荒れの諸症状を緩和、改善することができる。 However, the rough skin improving agent of the present invention can alleviate and improve various symptoms of rough skin.
本発明の肌荒れ改良剤において、前記卵巣膜から抽出された成分は、該卵巣膜をタンパク分解酵素で処理することにより抽出された成分であることが好ましい。また、前記卵巣膜としては、例えば鮭の卵巣膜を挙げることができる。 In the rough skin improving agent of the present invention, the component extracted from the ovarian membrane is preferably a component extracted by treating the ovarian membrane with a proteolytic enzyme. Examples of the ovarian membrane include a spider ovarian membrane.
次に、添付の図面を参照しながら本発明の実施の形態についてさらに詳しく説明する。図１は本実施形態の肌荒れ改良剤を８週間摂取した後の肌状態と摂取中止から２週間後の肌状態との比較を示すグラフ、図２は本実施形態の肌荒れ改良剤を摂取した場合とプラセボ（偽薬）を摂取した場合とのシワ係数の経時的変化を示すグラフ、図３は本実施形態の肌荒れ改良剤を摂取した場合とプラセボを摂取した場合とのシワ係数の変化量を示すグラフ、図４は本実施形態の肌荒れ改良剤を摂取した場合とプラセボを摂取した場合とのＩＧＦ−１値の経時的変化を示すグラフ、図５は本実施形態の肌荒れ改良剤を摂取した場合とプラセボを摂取した場合とのＩＧＦ−１値の変化量を示すグラフである。 Next, embodiments of the present invention will be described in more detail with reference to the accompanying drawings. FIG. 1 is a graph showing a comparison between the skin condition after ingesting the skin roughness improving agent of this embodiment for 8 weeks and the skin condition after 2 weeks of ingestion, and FIG. 2 is the case of ingesting the skin roughness improving agent of this embodiment. And FIG. 3 shows the amount of change in the wrinkle coefficient between the case of taking the rough skin improving agent of this embodiment and the case of taking placebo. Graph, FIG. 4 is a graph showing changes over time in IGF-1 values when ingesting the rough skin improving agent of the present embodiment, and when ingesting placebo, FIG. 5 is a case of ingesting the rough skin improving agent of the present embodiment It is a graph which shows the variation | change_quantity of the IGF-1 value at the time of ingesting a placebo.
本実施形態の肌荒れ改良剤は、例えば鮭等の魚類の卵巣膜から抽出された成分（以下、卵巣膜抽出成分と略記する）を含む。前記卵巣膜抽出成分は、例えば、魚卵から分離された前記卵巣膜を酵素処理してタンパク質を抽出した溶液を濾過し、得られた濾液を乾燥させる方法等により得ることができる。 The skin roughness improving agent of the present embodiment includes, for example, a component extracted from the ovarian membrane of fish such as salmon (hereinafter abbreviated as ovarian membrane extracted component). The ovarian membrane extract component can be obtained by, for example, a method of filtering a solution obtained by extracting the protein by enzymatic treatment of the ovarian membrane separated from fish eggs and drying the obtained filtrate.
前記方法では、具体的には、まず、鮭の卵巣膜を原料とし、該卵巣膜に対して水を卵巣膜：水＝１：１〜１：３の重量比で加えて撹拌、混合し、さらにタンパク分解酵素を卵巣膜の全量に対して１〜３重量％の範囲で添加し、４５〜５５℃の温度で３０分間〜５時間、好ましくは２時間加熱する。このようにすると、前記卵巣膜の成分のうち、前記タンパク分解酵素で分解された成分が水中に溶出し、該成分の水溶液が得られる。 Specifically, in the method, first, the ovarian membrane of the pupa is used as a raw material, and water is added to the ovarian membrane in a weight ratio of ovarian membrane: water = 1: 1 to 1: 3, and the mixture is stirred and mixed. Furthermore, proteolytic enzyme is added in the range of 1 to 3% by weight with respect to the total amount of the ovarian membrane, and heated at a temperature of 45 to 55 ° C. for 30 minutes to 5 hours, preferably 2 hours. If it does in this way, the component decomposed | disassembled with the said proteolytic enzyme will elute in water among the components of the said ovary membrane, and the aqueous solution of this component will be obtained.
次に、前記水溶液に含まれている前記タンパク分解酵素を失活する。前記失活は、例えば、前記水溶液を９０℃の温度で５分間加熱することにより行うことができる。 Next, the proteolytic enzyme contained in the aqueous solution is inactivated. The deactivation can be performed, for example, by heating the aqueous solution at a temperature of 90 ° C. for 5 minutes.
次に、前記水溶液を３０メッシュ程度の金網で簡易濾過し、未分解の卵巣膜等の粗大物を除去する。そして、得られた濾液に活性炭を添加して、該濾液の脱臭、脱色、脱脂を行う。前記濾液の脱臭、脱色、脱脂は、前記原料としての卵巣膜の全量に対して２〜４重量％の範囲の活性炭を該濾液に添加し、例えば６０℃の温度で３０分間加熱することにより行うことができる。 Next, the aqueous solution is simply filtered through a wire mesh of about 30 mesh to remove coarse materials such as undecomposed ovarian membranes. Then, activated carbon is added to the obtained filtrate to deodorize, decolorize, and degrease the filtrate. The deodorization, decolorization, and degreasing of the filtrate is performed by adding activated carbon in the range of 2 to 4% by weight to the total amount of the ovarian membrane as the raw material and heating the filtrate at a temperature of 60 ° C. for 30 minutes, for example. be able to.
前記活性炭による脱臭、脱色、脱脂処理後、前記濾液を例えばフィルタープレスにより濾過し、得られた濾液を、減圧下、例えば６０℃の温度で濃縮した後、例えば８０℃の温度に１０分間維持して滅菌する。そして、滅菌後の前記濾液をスプレードライにて乾燥させることにより、前記卵巣膜抽出成分を得ることができる。前記卵巣膜抽出成分は、アミノ酸、ペプチド、ビタミン、ミネラル、糖類、酵素、核酸及びその代謝物、各種成長因子、サイトカイン等を含んでいる。 After the deodorization, decolorization, and degreasing treatment with the activated carbon, the filtrate is filtered by, for example, a filter press, and the obtained filtrate is concentrated at a temperature of 60 ° C. under reduced pressure, for example, and then maintained at a temperature of 80 ° C. for 10 minutes, for example. And sterilize. Then, the ovarian membrane extract component can be obtained by drying the sterilized filtrate by spray drying. The ovarian membrane extract component contains amino acids, peptides, vitamins, minerals, sugars, enzymes, nucleic acids and their metabolites, various growth factors, cytokines, and the like.
本実施形態の肌荒れ改良剤は、前記卵巣膜抽出成分を、例えば錠剤等の形に製剤したものであり、例えば健康食品等の食品として摂取することにより、肌荒れの諸症状を緩和、改善することができる。 The rough skin improving agent of the present embodiment is prepared by formulating the ovarian membrane extract component in the form of, for example, a tablet. By taking it as a food such as a health food, various symptoms of rough skin are alleviated and improved. Can do.
次に、本発明の実施例と比較例とを示す。 Next, examples of the present invention and comparative examples will be described.
本実施例では、まず、鮭の卵巣膜抽出成分を錠剤の形に製剤して、肌荒れ改良剤を製造した。前記錠剤は、前記卵巣膜抽出物２４５ｍｇ、賦形剤（ラブリワックス（登録商標））５ｍｇからなり、８ｍｍの直径を備えている。 In this example, first, the ovarian membrane extract component of salmon was formulated in the form of tablets to produce a rough skin improving agent. The tablet consists of 245 mg of the ovarian membrane extract and 5 mg of excipient (Loveli wax (registered trademark)) and has a diameter of 8 mm.
次に、３８〜４２歳の健康な女性モニター１０名に、前記錠剤を健康食品として１日当たり４錠、８週間に亘って摂取させた。なお、各モニターは、１ヶ月前からサプリメント、薬品（漢方薬を含む）の摂取を行っていない。 Next, 10 healthy female monitors aged 38 to 42 years old took 4 tablets per day for 8 weeks as a health food. Each monitor has not taken supplements or medicines (including herbal medicines) since one month ago.
そして、各モニターの自己申告による肌状態について、摂取開始前と、摂取開始から８週間目と、摂取中止から２週間後との状態を比較した。結果を図１に示す。 And about the skin state by self-report of each monitor, the state before the start of ingestion, the 8th week after the start of ingestion, and the state after 2 weeks after the ingestion were compared. The results are shown in FIG.
また、摂取開始前、摂取開始から４週間目、摂取開始から８週間目に、次のようにして目尻のシワの目立ち度を測定した。まず、日本電気株式会社製のダイレクトスキンアナライザー（以下「ＤＳＡ」と記載する）を用いて、目尻にＤＳＡのセンサー部を接触させる。このとき、ＤＳＡは、目尻の画像を取り込み、センサー部に内蔵された光源（ＵＶストロボ）から３２０〜４００ｎｍの紫外線を皮膚に照射し、ＣＣＤカメラで表面画像を撮影した後に、画像全体の輝度分布（０〜６３段階）を求め、２値化画像を作成する。次に、得られた２値化画像を９×９のメッシュに分割し、１メッシュ中の黒画素比率が６０％以上であるメッシュの数（以下、「シワ係数」という）を求める。シワ係数は、シワの目立ち度を示しており、シワ係数が大きいほどシワが目立つことを意味している。 In addition, before the start of ingestion, 4 weeks after the start of ingestion and 8 weeks after the start of ingestion, the degree of wrinkle conspicuousness was measured as follows. First, using a direct skin analyzer (hereinafter referred to as “DSA”) manufactured by NEC Corporation, the sensor portion of the DSA is brought into contact with the corner of the eye. At this time, the DSA captures an image of the corner of the eye, irradiates the skin with ultraviolet light of 320 to 400 nm from a light source (UV strobe) built in the sensor unit, and takes a surface image with a CCD camera. (0 to 63 steps) is obtained and a binarized image is created. Next, the obtained binarized image is divided into 9 × 9 meshes, and the number of meshes (hereinafter referred to as “wrinkle coefficient”) having a black pixel ratio of 60% or more in one mesh is obtained. The wrinkle coefficient indicates the degree of wrinkle conspicuous, and the larger the wrinkle coefficient, the more noticeable the wrinkle is.
前記モニター１０人のシワ係数の平均値を図２に、摂取開始から４週間目まで、摂取開始から８週間目までのシワ係数の平均値の変化量を図３に、それぞれ示す。なお、図２中、摂取開始前を「０週」、摂取開始から４週間目を「４週」、摂取開始から８週間目を「８週」と記載し、図３中、摂取開始から４週間目までを「０−４週」、摂取開始から８週間目までを「０−８週」と記載する。
The average value of the wrinkle coefficient of the 10 monitors is shown in FIG. 2, and the amount of change in the average value of the wrinkle coefficient from the start of intake to the 4th week is shown in FIG. In FIG. 2, “0 week” before the start of intake, “4 weeks” after 4 weeks from the start of intake, and “8 weeks” after 8 weeks from the start of intake are shown in FIG. The week up to the
さらに、摂取開始前、摂取開始から４週間目、摂取開始から８週間目に、血液検査を行い、インシュリン成長因子−１（ＩＧＦ−１：Ｉｎｓｕｌｉｎ−ｌｉｋｅ Ｇｒｏｗｔｈ Ｆａｃｔｏｒ−１）値を測定した。なお、ＩＧＦ−１とは、インシュリンに非常に似た構造を持つポリペプチドである。ＩＧＦ−１値は加齢に伴って低下し、一旦下降したＩＧＦ−１値が再度上昇することはないといわれている。 Further, before the start of ingestion, 4 weeks after the start of ingestion and 8 weeks after the start of ingestion, blood tests were performed to measure insulin growth factor-1 (IGF-1: Insulin-like Growth Factor-1) values. IGF-1 is a polypeptide having a structure very similar to insulin. It is said that the IGF-1 value decreases with aging, and the once lowered IGF-1 value does not increase again.
前記モニター１０人のＩＧＦ−１値の平均値を図４に、摂取開始から４週間目まで、摂取開始から８週間目までのＩＧＦ−１値の平均値の変化量を図５に、それぞれ示す。
〔比較例〕
本比較例では、まず、前記実施例の肌荒れ改良剤に代えて、コーンスターチ１２５ｍｇ、乳糖１２５ｍｇからなるプラセボ（偽薬）を、直径８ｍｍの錠剤の形に製剤した。
The average value of the IGF-1 values of the 10 monitors is shown in FIG. 4, and the amount of change in the average value of the IGF-1 value from the start of intake to the fourth week is shown in FIG. .
[Comparative example]
In this comparative example, first, a placebo (placebo) consisting of 125 mg of corn starch and 125 mg of lactose was formulated in the form of a tablet having a diameter of 8 mm instead of the rough skin improving agent of the above-mentioned example.
次に、前記実施例とは異なる３８〜４２歳の健康な女性モニター１０名に、前記偽薬のカプセル剤を１日当たり４錠、８週間に亘って投与した。なお、各モニターは、１ヶ月前からサプリメント、薬品（漢方薬を含む）の摂取を行っていない。 Next, the placebo capsules were administered 4 times a day for 8 weeks to 10 healthy female monitors aged 38 to 42 years different from the Examples. Each monitor has not taken supplements or medicines (including herbal medicines) since one month ago.
そして、前記実施例と全く同一にして、目尻のシワの目立ち度とＩＧＦ−１値とを測定した。前記モニター１０人のシワ係数の平均値を図２に、摂取開始から４週間目、摂取開始から８週間目のシワ係数の平均値の変化量を図３に、前記モニター１０人のＩＧＦ−１値の平均値を図４に、摂取開始から４週間目、摂取開始から８週間目のＩＧＦ−１値の平均値の変化量を図５に、それぞれ示す。 Then, the degree of wrinkle conspicuousness and the IGF-1 value were measured in exactly the same manner as in the previous example. The average value of the wrinkle coefficient of the 10 monitors is shown in FIG. 2, the amount of change in the average value of the wrinkle coefficient at the 4th week from the start of intake and the 8th week from the start of intake is shown in FIG. The average value is shown in FIG. 4, and the amount of change in the average value of the IGF-1 value after 4 weeks from the start of intake and 8 weeks from the start of intake is shown in FIG.
図１から、本実施形態の肌荒れ改良剤（実施例）によれば、摂取開始前の肌状態よりも摂取開始から８週間目の肌状態の方が優れているとともに、摂取開始から８週間目の肌状態よりも摂取中止から２週間後の肌状態の方がさらに優れていることが明らかである。 From FIG. 1, according to the rough skin improving agent (Example) of this embodiment, the skin state at the 8th week from the start of intake is superior to the skin state before the start of intake, and the 8th week from the start of intake. It is clear that the skin condition after 2 weeks from the discontinuation of intake is even better than the skin condition.
従って、本実施形態の肌荒れ改良剤を摂取したことによって、肌荒れの諸症状が緩和、改善したと考えられる。さらに、本実施形態の肌荒れ改良剤には、効果の持続性があると考えられる。 Therefore, it is considered that various symptoms of rough skin were alleviated and improved by taking the rough skin improving agent of this embodiment. Furthermore, the rough skin improving agent of the present embodiment is considered to have a sustained effect.
また、図２から、本実施形態の肌荒れ改良剤によれば、摂取開始から４週間目には摂取開始前に比較してシワ係数が低下しており、摂取開始から８週間目には摂取開始から４週間目よりもさらに低下しており、単調に低下していることが明らかである。これに対して、プラセボ（比較例）によれば、摂取開始から４週間目には摂取開始前に比較してシワ係数が低下しているものの、摂取開始から８週間目には摂取開始前と同程度であり、単調な低下ではないことが明らかである。 Further, from FIG. 2, according to the rough skin improving agent of the present embodiment, the wrinkle coefficient is lower than that before the start of intake at 4 weeks from the start of intake, and the start of intake at 8 weeks after the start of intake. From the 4th week, it is further lower than the 4th week, and it is clear that it is decreasing monotonously. On the other hand, according to the placebo (comparative example), although the wrinkle coefficient is lower at 4 weeks after the start of intake than before the start of intake, It is clear that it is similar and not a monotonous decline.
また、図３から、本実施形態の肌荒れ改良剤によれば、シワ係数の低下量がプラセボよりも大きいことが明らかである。 Moreover, it is clear from FIG. 3 that according to the rough skin improving agent of the present embodiment, the amount of decrease in the wrinkle coefficient is larger than that of the placebo.
従って、本実施形態の肌荒れ改良剤を摂取したことによって、皮膚表面内側の新陳代謝が促進され、真皮部分の線維芽細胞の構造とヒアルロン酸等を含む細胞外マトリックス（ＥＣＭ）とが整えられたことにより、シワの深さが浅くなったと考えられる。 Therefore, by taking the skin roughness improving agent of this embodiment, the metabolism inside the skin surface was promoted, and the structure of the dermal fibroblasts and the extracellular matrix (ECM) containing hyaluronic acid and the like were prepared. It is thought that the depth of wrinkles became shallow.
さらに、図４から、本実施形態の肌荒れ改良剤によれば、摂取開始から４週間目には摂取開始前に比較してＩＧＦ−１値が増加しており、摂取開始から８週間目には摂取開始から４週間目よりもさらに増加しており、単調に増加していることが明らかである。これに対して、プラセボによれば、摂取開始から８週間目には摂取開始前に比較してＩＧＦ−１値が増加しているものの、摂取開始から４週間目には摂取開始前に比較して一旦ＩＧＦ−１値が減少しており、単調な増加ではないことが明らかである。 Furthermore, from FIG. 4, according to the rough skin improving agent of the present embodiment, the IGF-1 value increased compared to before the start of intake at 4 weeks from the start of intake, and after 8 weeks from the start of intake. It is further increased than the 4th week from the start of ingestion, and it is clear that the increase is monotonous. On the other hand, according to the placebo, although the IGF-1 value increased in the 8th week from the start of the intake compared to before the start of the intake, it was compared in the 4th week after the start of the intake before the start of the intake. It is clear that the IGF-1 value has once decreased and is not a monotonous increase.
また、図５から、本実施形態の肌荒れ改良剤によれば、ＩＧＦ−１値の増加量がプラセボよりも大きいことが明らかである。 Moreover, it is clear from FIG. 5 that according to the rough skin improving agent of this embodiment, the increase amount of IGF-1 value is larger than the placebo.
従って、本実施形態の肌荒れ改良剤を摂取したことによって、ＩＧＦ−１値が上昇したと考えられる。また、前述の肌荒れの諸症状の緩和、改善は、ＩＧＦ−１値の上昇も一因であると考えられる。 Therefore, it is considered that the IGF-1 value increased by taking the rough skin improving agent of the present embodiment. In addition, the above-described alleviation and improvement of various symptoms of rough skin are considered to be caused by an increase in IGF-1 value.
符号なし。 No sign.
Claims (3)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006183235A JP3899116B1 (en) | 2006-07-03 | 2006-07-03 | Skin roughening agent |
| KR1020070066257A KR101301037B1 (en) | 2006-07-03 | 2007-07-02 | Antiaging agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006183235A JP3899116B1 (en) | 2006-07-03 | 2006-07-03 | Skin roughening agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP3899116B1 JP3899116B1 (en) | 2007-03-28 |
| JP2008013442A true JP2008013442A (en) | 2008-01-24 |
Family
ID=37942117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006183235A Active JP3899116B1 (en) | 2006-07-03 | 2006-07-03 | Skin roughening agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3899116B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010083762A (en) * | 2008-09-29 | 2010-04-15 | Kyowa Yakuhin Kk | Climacteric disorders-improving agent and dietary supplement |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1938866B1 (en) * | 2006-12-22 | 2011-09-21 | Nippon Barrier Free Co. Ltd. | Cosmetic product comprising a component extracted from a Salmonidae fish ovarian membrane |
| JP5171752B2 (en) * | 2009-07-23 | 2013-03-27 | 株式会社ノエビア | Topical skin preparation |
| JP6085137B2 (en) * | 2012-10-02 | 2017-02-22 | 株式会社日本バリアフリー | Anti-aging agent |
-
2006
- 2006-07-03 JP JP2006183235A patent/JP3899116B1/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010083762A (en) * | 2008-09-29 | 2010-04-15 | Kyowa Yakuhin Kk | Climacteric disorders-improving agent and dietary supplement |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3899116B1 (en) | 2007-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5887630B2 (en) | Method for producing dipeptidyl peptidase-IV inhibitor | |
| TWI516280B (en) | Use of chenopodium formosanum extract for manufacture of composition for enhancing secretion of collagen and preventing cutaneous aging | |
| JP3899116B1 (en) | Skin roughening agent | |
| JP3946238B1 (en) | IGF-1 level increasing agent | |
| JP5027001B2 (en) | Enzyme-treated royal jelly and skin fibroblast growth promoter containing the same | |
| JP4917584B2 (en) | Processed solubilized bees, method for producing the same, antioxidant, ACE inhibitor, antihypertensive agent, dermal fibroblast proliferation promoter, fatigue recovery agent, blood flow improving agent, and solubilized bees Pharmaceuticals, cosmetics or food / drinks contained | |
| JPWO2011016220A1 (en) | Dipeptidyl peptidase-4 inhibitor | |
| Ramakrishnan et al. | A review on the processing of functional proteins or peptides derived from fish by-products and their industrial applications | |
| KR101615042B1 (en) | Composition for promoting lactic acid bacteria including an extract of ecklonia cava | |
| JP2002125662A (en) | Non-deactivated enzyme-reinforced composition | |
| JP4862235B2 (en) | Blood sugar level rise inhibitor | |
| JP3946239B1 (en) | Accelerating pulse wave aging index raising agent | |
| JP5449730B2 (en) | Menopause ameliorant and nutritional supplement | |
| JP2008037770A (en) | Anti-aging agent | |
| JP6544503B2 (en) | Cosmetic composition and functional food containing collagenase inhibitor and collagenase inhibitor | |
| JPH07285881A (en) | Excitometabolic agent for alcohol | |
| Sethuramalingam et al. | Anti-oxidant, anti-inflammatory and anti-atherosclerotic activity of bioactive peptide HPAEDR isolated from Catla catal muscle on LPS induced inflammation on 246.7 raw macrophage cells and HCF induced hyperlipidemic Zebrafish Larvae | |
| JP2006328016A (en) | Composition for treating and preventing chapped skin | |
| JP6154029B2 (en) | Sleep improving agent, non-REM sleep time increasing agent and sedative | |
| JP6245924B2 (en) | Glucose level rise inhibitor, Glucose level rise inhibitory food, and Glucose level rise inhibitory cosmetic | |
| JP2017195830A (en) | Food composition for adiposity prevention | |
| JP5668018B2 (en) | Alcohol intake disorder preventive | |
| WO2024090464A1 (en) | Skin improvement agent having fermented extract as main raw material | |
| KR102602070B1 (en) | A composition for improving intestinal health comprising Salicornia herbacea mixed fermentation product | |
| WO2012133223A1 (en) | Matrix metalloprotease (mmp) production inhibitor for oral use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061205 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20061222 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 3899116 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110105 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110105 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120105 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120105 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130105 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130105 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140105 Year of fee payment: 7 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |